Clinical Trial

Effect of Cytokine-induced Killer Cells for Stage I-II Malignant Gliomas

Name: Effect of Cytokine-induced Killer Cells for Stage I-II Malignant Gliomas — clinical trial record (NCT02494804)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

The purpose of this study is to determine whether combining of Temozolomide and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with Malignant Gliomas. The effectiveness and safety of CIK cells for the treatment of Malignant Glioma is also evaluated.

Trial Details

NCT Number	NCT02494804
Lead Sponsor	The First People's Hospital of Changzhou
Conditions	Cytokine-Induced Killer Cells, Milignant Gliomas
Enrollment	80 participants
Start Date	2015-07
Primary Completion	2028-07 (estimated)
Study Completion	2030-07 (estimated)
Updated on ClinicalTrials.gov	2015-07-10